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Abstract: Lactation is associated with reduced postpartum weight retention and a lower risk
of several cardiometabolic disorders in population-based studies. We examined the association
between lactation and long-term thyroid function among women with history of gestational
diabetes mellitus (GDM), a high-risk population for subsequent metabolic complications. The study
included 550 women who developed GDM in the Danish National Birth Cohort (1996–2002) and
followed-up in the Diabetes & Women’s Health Study (2012–2014). We assessed adjusted associations
between cumulative lactation duration and concentrations of thyroid stimulating hormone (TSH),
free triiodothyronine (fT3), and free thyroxine (fT4) measured at follow-up. Women with longer
cumulative lactation duration tended to have higher fT3 levels (adjusted β and 95% confidence
interval (CI) for ≥12 months vs. none: 0.19 (0.03–0.36); p-trend = 0.05). When restricted to women
with a single lifetime pregnancy to control for parity (n = 70), women who lactated for >6 months
(vs. none) had higher fT3 levels (0.46 pmol/L (0.12–0.80); p-trend = 0.02) and a higher fT3:fT4 ratio
(0.61 (0.17–1.05); p-trend = 0.007). Our findings suggested that a longer duration of lactation may be
related to greater serum fT3 levels and fT3:fT4 ratio 9–16 years postpartum among Danish women
with a history of GDM. The association was particularly pronounced among women who only had
one lifetime pregnancy.
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1. Introduction
The thyroid gland is involved in several physiological processes, including glucose metabolism,
muscle repair, cardiovascular function, and thermogenesis [1]. Thyroid dysfunction may be manifested
as clinical, subclinical, or autoimmune, depending on the levels of thyroid hormones (thyroid
stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine (fT4)) and anti-thyroid
antibodies (e.g., thyroperoxidase antibody (anti-TPO), and thyroglobulin antibody (anti-TG)). Women
who develop diabetes in pregnancy, or gestational diabetes mellitus (GDM), are particularly subject to
a substantially increased risk for cardiometabolic disorders [2]. Given the importance of thyroid
hormones in maintaining the function of multiple systems and regulatory pathways related to
cardiometabolic functions, the identification of potentially modifiable factors related to thyroid function
among GDM women is of important clinical and public health significance.
Lactation has been associated with several health benefits in women [3]. Foremost, postpartum
weight retention is reduced in women who breastfed their children [3]. In addition, women with
a longer lifetime duration of lactation are at lower risk for cardiometabolic disorders, including
cardiovascular disease, type 2 diabetes mellitus (T2DM), and hypertension [3]. Interestingly, animal
data also demonstrate that increasing lactation duration is associated with heightened thyroid
activity, resulting in increased levels of biologically active thyroid hormone, triiodothyronine (T3) [4].
Specifically, in bovine models, mRNA transcripts for the enzyme responsible for generating T3 were
6-fold greater with 90 days of lactation compared to levels preceding birth [4]. A link between lactation
and thyroid function may lie in the reduction of postpartum weight retention, as weight gain was
previously highly associated with TSH and fT4 humans [5]. However, human data are lacking for the
influence of lactation on long-term thyroid function among both the general population and women
with a history of GDM in particular.
The objective of this study was to examine the association between lactation duration and
long-term thyroid function among a high-risk cohort of women with a history of GDM [6–13]. We
hypothesize that a longer cumulative lactation duration is associated with improved thyroid function,
approximately 9–16 years after the index GDM pregnancy.
2. Materials and Methods
2.1. Study Design
In the Diabetes & Women’s Health (DWH) Study [14], we followed up women identified as
having GDM during the index pregnancy of the Danish National Birth Cohort (DNBC) [15]. The
DNBC collected data on maternal demographics, perinatal exposures, and health conditions through
four telephone interviews conducted at gestational weeks 12 and 30, and 6 and 18 months postpartum
(1996–2002). The DWH Study (2012–2014) enrolled 790 women who had GDM during their index
pregnancy, 9–16 years after their enrollment in the DNBC. This analysis was limited to women who
completed the DWH Study clinical exam in which biospecimens were collected (n = 619) and for whom
thyroid markers were available (n = 611; 99.0%). Women reporting thyroid disease before the index
DNBC pregnancy (n = 18; 3.0%) were excluded. We further excluded participants with missing data
on breastfeeding duration (n = 43; 7.3%) to arrive at the final analytic sample (n = 550). All participants
provided informed consent. The study was approved by the Regional Scientific Ethical Committee
(VEK) of the Capital Region of Denmark (record No. H-4-2013-129).
2.2. Ascertainment of Cumulative Lactation History after Index GDM Pregnancy
At the DWH Study follow-up, women retrospectively reported the duration of lactation for each
of their pregnancies. The cumulative duration of lactation was calculated by summing the number
of lactating months following each birth and was categorized as: none, <6, 6 to <12, or ≥12 months.
Because we lacked covariate information for pregnancies before the index DNBC pregnancy, we
calculated lifetime lactation duration starting at the index pregnancy and thus, adjusted for parity at
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the index pregnancy and performed further analyses limited to women who were nulliparous at the
index pregnancy.
To assess the validity of recalled lactation duration, we examined the correlation between
lactation duration proximally reported for the index DNBC pregnancy at 6 and 18 months postpartum
interviews, and the duration recalled for the corresponding pregnancy on the DWH Study follow-up
questionnaire 9–16 years postpartum. The correlation was high (r = 0.81), and 69.9% of women
accurately reported the duration within 1 month. In our analyses, we use the retrospectively
reported lactation data as it captured the lactation history over all pregnancies as opposed to only the
index pregnancy.
2.3. Thyroid Function
At the DWH Study follow-up clinical exam, fasting venous blood samples were collected,
processed within 1 h, and stored at −80 ◦C until being analyzed by a central laboratory following a
standardized protocol. All samples were assayed in a single batch by a certified clinical laboratory at
the University of Minnesota. Concentrations of thyroid stimulating hormone (TSH) (mIU/L) were
measured using a sandwich immunoassay (Roche Diagnostics, Indianapolis, IN, USA). Concentrations
of free triiodothyronine (fT3) (pmol/L), free thyroxine (fT4) (ng/dL), anti-TPO (IU/mL), and
anti-TG (thyroglobulin antibody; IU/mL) were measured using a competitive immunoassay (Roche
Diagnostics, Indianapolis, IN, USA). The fT3:fT4 ratio was calculated by dividing serum concentrations
of fT3 (pmol/L) by fT4 (ng/dL). The inter-assay coefficients of variance (CV) were all <6.2% for fT3,
fT4, and TSH and <15.1% for the anti-TPO and anti-TG antibodies.
Thyroid function was assessed based on continuous levels of thyroid hormones (TSH, fT3,
fT4, fT3:fT4). Additionally, following the American Thyroid Association guidelines, subclinical
hypothyroidism (SCH) was defined as having an elevated TSH (normal range 0.45–4.12 mIU/L) with
normal fT4 levels (0.93–1.7 ng/dL) [16]. Subclinical hyperthyroidism was defined as having low
to undetectable TSH with normal levels of fT3 (normal range 3.53–6.45 pmol/L) and fT4 (normal
range 0.93–1.7 ng/dL) [16,17]. Women with both TSH and fT4 levels within the normal range were
classified as euthyroid. Participants who did not meet the criteria for euthyroid, SCH, or subclinical
hyperthyroidism were classified as “other”. Lastly, participants were categorized as positive for
anti-TPO and anti-TG if their antibody levels were above lab reference ranges (anti-TPO: ≥35 IU/mL;
anti-TG: ≥115 IU/mL).
2.4. Covariates
Data on potential confounders were available from interview responses at the baseline index
DNBC pregnancy. Covariates selected a priori included age (years), socioeconomic status (high or
medium level professional, skilled worker, other (student, unskilled, unemployed)), nulliparity (yes,
no), smoking during pregnancy (any, none), alcohol during pregnancy (any, none) and pre-pregnancy
body mass index (BMI) (<25, 25–29.9, ≥30.0 kg/m2) calculated from self-reported height and
pre-pregnancy weight. Pre-pregnancy weight was not reported at the time of the index pregnancy
for a small sub-set of women (n = 41), however, pre-pregnancy weight was reported on the DWH
Study follow-up questionnaire. For women who reported a pre-pregnancy weight at both instances
the weight was highly correlated (r = 0.89) and thus, was used to supplement the missing data when
available (n = 40).
We considered effect modification by several key variables at the DWH Study follow-up, including
T2DM status, age, menopausal status, and long-term weight change since the index pregnancy. T2DM
status was classified based on HbA1c levels ≥6.5%, fasting glucose ≥7 mmol/L, 2 h glucose after
75 g oral glucose tolerance test ≥11.1 mmol/L, or self-report of physician diagnosis at follow-up [18].
Type 1 diabetes at follow-up was based on self-report of physician diagnosis. Women self-reported
their menopausal status (yes, no). Age was categorized according to the median age in the cohort at
follow-up (<45 years vs. ≥45 years). Long-term weight change was calculated as the difference in
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measured weight at the DWH follow-up and self-reported pre-pregnancy weight at the DNBC index
pregnancy and was categorized according to the median level (<4.1 kg vs. ≥4.1 kg).
2.5. Statistical Analysis
Characteristics of study participants were presented overall and by cumulative lactation duration
after the index pregnancy. Differences across lactation duration were described as mean (standard
deviation, SD) for continuous variables and frequency (%) for categorical variables. Bivariate
associations were evaluated using the one-way Analysis of Variance (ANOVA) for continuous variables
and the χ2 test for categorical variables.
For each lactation category, we used generalized linear models to estimate the unadjusted and
adjusted differences in concentrations of TSH, fT3, fT4 and fT3:fT4, by categories of cumulative
lactation duration, with no lactation as the reference group. We assessed linear trends (p-trend) by
using the median for each category of lactation duration as a continuous exposure. We used logistic
regression to estimate unadjusted and adjusted odds ratios (ORs) for SCH, anti-TG positivity, and
anti-TPO positivity. All multivariable models were adjusted for potential confounders measured at
the index pregnancy and included age, socioeconomic status, pre-pregnancy BMI, parity, smoking
during pregnancy, and alcohol consumption during pregnancy. An unknown category was used to
account for the small proportion of missing covariate data. Due to a small number of women with
SCH (n = 17), the models were unstable and results for SCH are not reported.
To ensure that our findings were not biased by pregnancy or lactation characteristics prior to the
index DNBC pregnancy and to remove the effect of parity, we repeated our analyses with only women
who had one pregnancy overall and thus, were nulliparous at the index pregnancy. By limiting our
sample, we also reduced recall bias from women with multiple pregnancies. In this subset of women,
lactation was based on only a single pregnancy and was categorized as none, >0 to 6 months, and
>6 months.
To understand whether the observed findings differed across several clinically distinct subgroups
of individuals, we tested for a multiplicative interaction with the following characteristics measured at
the DWH Study follow-up: age, menopausal status, T2DM status, and long-term weight change.
Two-tailed p-values < 0.05 were considered significant. All statistical analyses were performed
using SAS version 9.4 (SAS Institute, Cary, NC, USA).
3. Results
Overall, the median cumulative duration of lactation after a median of one (interquartile range
1–2) pregnancy was 9 (interquartile range 4–15) months, including a lactation duration of 0 months
for women who reported never lactating (n = 62, 11.3%). With an increasing duration of lactation,
women tended to be lower in pre-pregnancy BMI, of older age, multiparous, and report no alcohol
consumption during the index pregnancy. Thyroid biomarkers for most participants were within
the euthyroid range (n = 476, 86.6%), while the remainder were classified as SCH (n = 19, 3.5%),
hyperthyroid (n = 7, 1.3%), or other (n = 48, 8.7%). Participants in the “other” category did not meet
the criteria for SCH, hyperthyroidism, or euthyroid. Several participants were positive for anti-TPO
(n = 78, 14.2%) and anti-TG (n = 69, 12.6%) (Table 1).
There was no significant association between lactation and odds of anti-TG positivity or anti-TPO
positivity (Table 2). Table 3 shows the unadjusted and adjusted differences in women’s thyroid marker
levels for each category of cumulative lactation, compared to women who never lactated. Women
with a longer lactation duration had higher fT3 levels at follow-up, (adjusted β and 95% confidence
interval (CI) for ≥12 months vs. none: 0.19 (0.03, 0.36); p-trend = 0.05). No significant associations
were observed between lactation and concentrations of TSH, fT4, or the fT3:fT4 ratio at follow-up.
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Table 1. Participant characteristics overall and by lactation history from the Diabetes & Women’s
Health Study.
Characteristics
Ascertained at Index
Pregnancy (1996–2002)
Overall
(n = 550)
Cumulative Lactation Duration, Months
p *None
(n = 62)
>0 to < 6
(n = 106)
6 to < 12
(n = 171)
≥12
(n = 211)
Age, years 31.5 (4.5) 31.1 (4.5) 31.8 (4.0) 32.2 (4.6) 30.8 (4.4) 0.01
Pre-pregnancy BMI, kg/m2 <0.001
Unknown 30 (5.5) 6 (9.7) 8 (7.6) 6 (3.5) 10 (4.7)
<25.0 221 (40.2) 13 (21.0) 30 (28.3) 76 (44.4) 102 (48.3)
25.0–29.9 143 (26.0) 16 (25.8) 26 (24.5) 45 (26.3) 56 (26.5)
≥30.0 156 (28.4) 27 (43.6) 42 (39.6) 44 (25.7) 43 (20.4)
Occupation <0.001
Unknown 49 (8.9) 13 (21.0) 12 (11.3) 9 (5.3) 15 (7.1)
Professional 254 (46.2) 20 (32.3) 31 (29.3) 82 (48.0) 121 (57.4)
Skilled worker 152 (27.6) 16 (25.8) 41 (38.7) 47 (27.5) 48 (22.8)
Other (unskilled worker,
unemployed, student) 95 (17.3) 13 (21.0) 22 (20.8) 33 (19.3) 27 (12.8)
Parity <0.001
Unknown 46 (8.4) 13 (21.0) 11 (10.4) 8 (4.7) 14 (6.6)
0 200 (36.4) 26 (41.9) 32 (30.2) 41 (24.0) 101 (47.9)
≥1 304 (55.3) 23 (37.1) 63 (59.4) 122 (71.4) 96 (45.5)
Drank any alcohol while
pregnant <0.001
Unknown 21 (3.8) 8 (12.9) 4 (3.8) 3 (1.8) 6 (2.8)
No 244 (44.4) 33 (53.2) 42 (39.6) 68 (39.8) 101 (47.9)
Yes 285 (51.8) 21 (33.9) 60 (56.6) 100 (58.5) 104 (49.3)
Smoked while pregnant 0.002
Unknown 21 (3.8) 8 (12.9) 4 (3.8) 3 (1.8) 6 (2.8)
No 383 (69.6) 34 (54.8) 69 (65.1) 124 (72.5) 156 (73.9)
Yes 146 (26.6) 20 (32.3) 33 (31.1) 44 (25.7) 49 (23.2)
Characteristics ascertained
at follow-up (2012–2014)
Age, year 43.6 (4.6) 43 (4.6) 43.9 (4.3) 44.3 (4.7) 43.1 (4.6)
Weight change, kg 0.36
Unknown 8 (1.5) 2 (3.2) 2 (1.9) 2 (1.2) 2 (1.0)
<4.1 269 (48.9) 35 (56.5) 52 (49.1) 89 (52.1) 93 (44.1)
≥4.1 273 (49.6) 25 (40.3) 52 (49.1) 80 (46.8) 116 (55.0)
Diabetes 0.02
Unknown 6 (1.1) 2 (3.2) 2 (1.9) 1 (0.6) 1 (0.5)
No 388 (70.6) 37 (59.7) 65 (61.3) 120 (70.2) 166 (78.7)
Type 1 14 (2.6) 1 (1.6) 5 (4.7) 4 (2.3) 4 (1.9)
Type 2 142 (25.8) 22 (35.5) 34 (32.1) 46 (26.9) 40 (19)
Post-Menopausal 0.047
Unknown 6 (1.1) 2 (3.2) 2 (1.9) 1 (0.6) 1 (0.5)
No 463 (84.2) 49 (79) 87 (82.1) 137 (80.1) 190 (90.1)
Yes 81 (14.7) 11 (17.7) 17 (16) 33 (19.3) 20 (9.5)
TSH (mIU/L) 2.1 (1.5) 2.2 (1.5) 2 (1.3) 2.1 (1.3) 2.2 (1.8) 0.90
fT3 (pmol/L) 4.6 (0.6) 4.5 (0.6) 4.6 (0.7) 4.6 (0.5) 4.7 (0.6) 0.16
fT4 (ng/dL) 1.1 (0.2) 1.1 (0.2) 1.2 (0.2) 1.1 (0.2) 1.2 (0.2) 0.67
fT3:fT4 ratio 4.1 (0.6) 4.1 (0.7) 4 (0.6) 4.1 (0.7) 4.1 (0.6) 0.59
Anti-TPO positive 78 (14.2) 8 (12.9) 13 (12.3) 30 (17.5) 27 (12.8) 0.51
Anti-TG Positive 69 (12.6) 5 (8.1) 9 (8.5) 26 (15.2) 29 (13.7) 0.25
Data are presented as mean (standard deviation; SD) for continuous variables and n (%) for categorical variables.
* Bolded p values represent significant global differences in participant characteristics across lactation duration
categories. Abbreviations: BMI, body mass index; TSH, thyroid stimulating hormone; fT3, free triiodothyronine;
fT4, free thyroxine; anti-TOP, thyroperoxidase antibody; anti-TG, thyroglobulin antibody.
Nutrients 2018, 10, 938 6 of 12
Table 2. Odds of thyroid autoimmunity 9 to 16 years postpartum according to lactation history among
women with a history of gestational diabetes, Diabetes & Women’s Health Study.
Outcome n UnadjustedOR (95% CI) p *
Adjusted OR 1
(95% CI)
p *
TG-positive 2
≥12 months 211 1.82 (0.67, 4.91) 0.23 2.63 (0.74, 9.37) 0.13
6 to <12 months 171 2.04 (0.75, 5.58) 0.16 2.88 (0.80, 10.27) 0.10
<6 months 106 1.06 (0.34, 3.31) 0.92 1.72 (0.44, 6.82) 0.43
None 62 1.00 (reference) 1.00 (reference)
TPO-positive 2
≥12 months 211 0.99 (0.43, 2.31) 0.98 0.93 (0.36, 2.39) 0.88
6 to <12 months 171 1.44 (0.62, 3.33) 0.40 1.17 (0.46, 2.99) 0.74
<6 months 106 0.94 (0.37, 2.42) 0.90 0.70 (0.24, 2.03) 0.52
None 62 1.00 (reference) 1.00 (reference)
1 Model was adjusted for the following covariates, measured at the index pregnancy: age, pre-pregnancy
body mass index (unknown, <25, 25–29.9, ≥30.0 kg/m2), occupation (unknown, professional, skilled worker,
unskilled/unemployed/student), nulliparity (unknown, yes, no), smoking during pregnancy (unknown, any, none),
and alcohol consumption during pregnancy (unknown, any, none). 2 TG, thyroglobulin antibody; TPO, thyroid
peroxidase antibody. * p-values represent significance in the difference in odds of TG- or TPO- positivity for each
category of lactation duration compared to no lactation.
Table 3. Thyroid biomarker levels 9 to 16 years postpartum according to lactation history among
women with a history of gestational diabetes, Diabetes & Women’s Health Study.
Thyroid
Biomarker n
Unadjusted β
Estimate (95% CI) p-Trend *
Adjusted 1 β
Estimate (95% CI)
p-Trend *
TSH (mIU/L) 0.79 0.87
≥12 months 211 −0.05 (−0.48, 0.38) −0.03 (−0.47, 0.41)
6 to <12 months 171 −0.07 (−0.51, 0.37) −0.03 (−0.49, 0.43)
<6 months 106 −0.17 (−0.64, 0.31) −0.13 (−0.61, 0.35)
None 62 Reference Reference
fT3 (pmol/L) 0.03 0.05
≥12 months 211 0.18 (0.01, 0.34) 0.19 (0.03, 0.36)
6 to <12 months 171 0.10 (−0.07, 0.27) 0.15 (−0.02, 0.32)
<6 months 106 0.10 (−0.08, 0.28) 0.13 (−0.05, 0.31)
None 62 Reference Reference
fT4 (ng/dL) 0.65 0.55
≥12 months 211 0.03 (−0.02, 0.07) 0.03 (−0.02, 0.07)
6 to <12 months 171 0.02 (−0.03, 0.07) 0.03 (−0.02, 0.07)
<6 months 106 0.03 (−0.02, 0.08) 0.04 (−0.01, 0.09)
None 62 Reference Reference
fT3:fT4 ratio 0.24 0.30
≥12 months 211 0.04 −0.14, 0.23) 0.06 (−0.13, 0.25)
6 to <12 months 171 −0.01 (−0.20, 0.18) 0.03 (−0.16, 0.23)
<6 months 106 −0.06 (−0.26, 0.14) −0.05 (−0.25, 0.15)
None 62 Reference Reference
1 Model was adjusted for the following covariates, measured at the index pregnancy: age, pre-pregnancy
body mass index (unknown, <25, 25–29.9, ≥30.0 kg/m2), occupation (unknown, professional, skilled worker,
unskilled/unemployed/student), nulliparity (unknown, yes, no), smoking during pregnancy (unknown, any, none),
and alcohol during pregnancy (unknown, any, none). * Bolded p-trend values represent significant linear trends in
thyroid biomarker levels with increasing lactation duration. We assessed p-trends by using the median for each
category of lactation duration as a continuous exposure.
Although there were significant differences in mean levels of several thyroid biomarkers according
to long-term weight change and diabetes status at follow-up (Table A1), there was no variation in the
lactation duration–thyroid function association according to maternal weight change, diabetes status,
or age at follow-up (p for interaction >0.05). There was a significant interaction between lactation
duration and menopause status for the outcomes of fT3 (p = 0.02) and the fT3:fT4 ratio (p = 0.03).
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The results were null among pre-menopausal women, but stronger among post-menopausal women
such that a lactation duration of ≥12 months was associated with higher fT3 levels by 0.47 pmol/L
compared to women who never lactated (Table A2).
To tease apart the effect of lactation from the number of pregnancies, we restricted the analyses
to women with a single lifetime pregnancy (n = 70). Women with a cumulative lactation duration
>6 months had significantly higher levels of fT3 (0.46 pmol/L (0.12, 0.80); p-trend = 0.02) and a
higher fT3:fT4 ratio (0.61 (0.17, 1.05); p-trend = 0.007) than women who had never lactated (Table 4).
In addition, there was a significant trend (p = 0.04) of increasing TSH with increasing lactation duration.
Table 4. Thyroid biomarker levels 9 to 16 years postpartum according to lactation history among
women with a history of gestational diabetes who had a single lifetime pregnancy, Diabetes & Women’s
Health Study.
Thyroid
Biomarker n
Unadjusted β
Estimate (95% CI) p-Trend *
Adjusted 1 β
Estimate (95% CI)
p-Trend *
TSH (mIU/L) 0.045 0.04
>6 months 24 0.67 (−0.09, 1.44) 0.78 (−0.03, 1.58)
>0 to 6 months 26 −0.04 (−0.79, 0.71) 0.14 (−0.65, 0.94)
None 20 Reference Reference
fT3 (pmol/L) 0.17 0.02
>6 months 24 0.22 (−0.12, 0.56) 0.46 (0.12, 0.80)
>0 to 6 months 26 0.04 (−0.29, 0.38) 0.27 (−0.06, 0.60)
None 20 Reference Reference
fT4 (ng/dL) 0.07 0.36
>6 months 24 −0.09 (−0.20, 0.01) −0.05 (−0.15, 0.06)
>0 to 6 months 26 −0.03 (−0.14, 0.07) −0.02 (−0.12, 0.09)
None 20 Reference Reference
fT3:fT4 ratio 0.009 0.007
>6 months 24 0.55 (0.12, 0.99) 0.61 (0.17, 1.05)
>0 to 6 months 26 0.12 (−0.31, 0.55) 0.25 (−0.18, 0.69)
None 20 Reference Reference
1 Model was adjusted for the following covariates, measured at the index pregnancy: age, pre-pregnancy
body mass index (unknown, <25, 25–29.9, ≥30.0 kg/m2), occupation (unknown, professional, skilled worker,
unskilled/unemployed/student), nulliparity (unknown, yes, no), smoking during pregnancy (unknown, any, none),
and alcohol during pregnancy (unknown, any, none). * Bolded p-trend values represent significant linear trends in
thyroid biomarker levels with increasing lactation duration. We assessed p-trends by using the median for each
category of lactation duration as a continuous exposure.
4. Discussion
In the present study following women 9–16 years after GDM pregnancy, a high-risk population for
cardiometabolic complications, we examined whether cumulative duration of lactation is associated
with long-term thyroid function. Findings from this study suggested that a longer cumulative lactation
duration is associated with higher serum fT3 levels and fT3:fT4 ratio approximately 9–16 years
after the index pregnancy. The positive association between lactation duration and fT3 levels
was more pronounced among nulliparous women at the index pregnancy. While the strengths
of these associations are modest, they highlight novel findings, extending the existing literature
which demonstrates long-term associations between women’s lifetime duration of lactation and
cardiometabolic health to potentially include thyroid function as a novel endpoint [19–21].
An important feature of our study was distinguishing the effect of cumulative duration of lactation
from parity, as these variables are highly correlated. We accomplished this by restricting the study
specifically to women who were nulliparous at the index pregnancy and had only a single lifetime
pregnancy. The results of our analyses were more robust among this subset, as we removed any
residual confounding due to parity. It was meaningful to analyze this subset, as we observed an
association between lactation and thyroid biomarker levels even within the shorter lactation periods
following only a single birth.
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Prior studies have observed that a longer lactation duration is related to lower levels of risk for
breast and ovarian cancer, cardiovascular disease, diabetes, hypertension, and hyperlipidemia [3].
There has been limited clinical or epidemiologic research on lactation and long-term maternal thyroid
function. Our study adds an intriguing piece to the prior work by linking lactation duration with
long-term thyroid function, as we provide suggestive evidence that women who lactated for longer
durations of time had higher levels of serum fT3 later in life. Interestingly, we observed that women
with even 6 months of lactation, compared to none, had higher levels of fT3 and the fT3:fT4 ratio.
Several hypotheses may explain the biological mechanisms associating lactation with long-term
maternal metabolic health. To support the developing fetus and prepare the mother for lactation, there
is an increase in visceral adiposity, circulating lipids, and insulin levels during pregnancy [22]. It is
hypothesized that a prolonged duration of lactation helps to rapidly and more completely reverse
these metabolic changes by mobilizing the fat stores accumulated during pregnancy [22]. This “reset”
to the maternal metabolism may reduce women’s risk for future metabolic diseases, possibly including
thyroid dysfunction. Animal models also offer unique insight into the biological pathways linking
lactation and thyroid function. In bovine models, the quantity of mRNA transcripts in the mammary
gland for iodothyronine deiodinase type II (DIO2), the enzyme responsible for generating T3, the
biologically active thyroid hormone, from inactive T4, increased with lactation duration [4]. This
observation is consistent with our findings that a longer duration of lactation is associated with greater
fT3 levels and fT3:fT4, as fT3 is the form of T3 that is in circulation, and the fT3:fT4 ratio is a proxy
for the conversion from T4 to T3. Furthermore, we hypothesized that a potential mechanism for the
association between lactation and thyroid function may have been through weight change, yet we did
not observe any evidence for this. Lastly, the association between GDM and T2DM has been previously
studied and served as the impetus for this research to look beyond cardiometabolic disorders and
extend to thyroid metabolism. However, it should be noted that the results were consistent regardless
of T2DM status at follow-up. Further research into the mechanisms is warranted.
Although the effect sizes observed in our study do not clinically alter euthyroid status, prior
research has demonstrated an association between small changes in thyroid hormone levels and clinical
outcomes, even within the euthyroid range. Specifically, the importance of T3 in overall health and
metabolic function has been demonstrated among patients with end-stage renal disease, hemodialysis,
chronic heart failure, and cerebral infarction who also had clinically low T3 (i.e., low T3 syndrome) and
were receiving T3 replacement therapy [23–26]. Conversely, higher fT3 levels have been associated
with several parameters of metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and
insulin resistance among cohorts of healthy euthyroid individuals [27–30]. The conflicting results from
these studies warrant further investigation of lifetime lactation and thyroid disease, beyond clinical
biomarkers. Lactation was not associated with thyroid autoimmunity status (i.e., TGO-positivity and
TG-positivity); however, the sample size in the current study may have been too small to detect an
association. Further research, with a larger sample and longer follow-up time, may be necessary
to understand the clinical significance of higher fT3 levels associated with a longer duration of
cumulative lactation.
There are several strengths to our study, including the hybrid study design, combining DNBC
pregnancy data with follow-up data from the DWH Study. This study design provided the unique
opportunity to follow a large high-risk cohort of women with a history of GDM for over a decade,
and to understand their long-term health consequences and modifiable risk factors for specific health
outcomes. Additionally, lactation duration, which was reported by women immediately following
the index DNBC pregnancy, was highly correlated with women’s reported duration at the DWH
Study follow-up 9–16 years later. This also helped to validate women’s recall of lactation duration
for the additional births. Our study was further strengthened by consideration of several risk factors
for thyroid function reported during the index DNBC pregnancy, including pre-pregnancy BMI,
age, socioeconomic status, smoking during pregnancy, and alcohol consumption during pregnancy.
Finally, our study is generalizable to Danish women with a history of GDM. While our findings
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may not be generalizable to all women, women with GDM represent a unique high-risk model for
metabolic dysfunction.
Several limitations warrant discussion. First, the cumulative duration of lactation was calculated
following the index pregnancy because we did not have detailed lactation data and related covariates
before the index pregnancy. However, to account for potential confounding from previous lactation
history, we adjusted for the number of pregnancies before the index pregnancy (i.e., parity at the index
pregnancy). In addition, we conducted an analysis restricted to women for whom the index pregnancy
was their first pregnancy and thus had no prior lactation history. In these analyses, we observed a
similar, but stronger positive association between lactation duration and thyroid marker levels. Second,
we did not have clear data on how many additional pregnancies were complicated by GDM. Third,
we assessed thyroid biomarkers only at a single follow-up and we were unaware of baseline thyroid
marker levels before pregnancy or during the interim between the index GDM pregnancy and follow
up. While we excluded women with known thyroid disorders prior to pregnancy, we did not have
information on the development of, and treatment for, thyroid disease during the period between
the index GDM pregnancy and follow up. Fourth, we did not have the power to test for associations
between lactation and clinical end points related to thyroid function, such as SCH and other thyroid
diseases. Lastly, we did not have data from women on reasons for discontinuing breastfeeding or
choosing not to breastfeed, and thus we cannot tease out confounding from other factors (i.e., social
factors, milk supply, etc.) that may have contributed to lactation duration.
5. Conclusions
In Danish women with a history of GDM, our findings suggest a positive association between
a longer duration of lactation and higher levels of thyroid hormone 9–16 years postpartum, even
among women with a single lifetime pregnancy. Here we identified lactation as a novel potential
modifiable factor for thyroid function, and with replication, these findings may add thyroid function
to the wide-array of long-term cardiometabolic outcomes associated with increased lactation duration.
As with the findings related to metabolic health, more research is needed to understand the mechanisms
behind our findings. A longer follow-up period may help further understanding of the clinical impact
of elevated fT3 levels associated with longer lactation duration.
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Appendix A
Table A1. Thyroid biomarkers according to participant characteristics at follow-up (2012–2014).
Characteristics Ascertained
at Follow-Up (2012–2014) n
Thyroid Biomarkers
TSH (mIU/L) fT3 (pmol/L) fT4 (ng/dL) fT3:fT4 Ratio
Age
Unknown 6 1.73 (1.10) 4.0 (1.38) 1.09 (0.41) 3.74 (0.46)
<45 314 2.09 (1.66) 4.65 (0.60) 1.14 (0.15) 4.12 (0.66)
≥45 230 2.20 (1.32) 4.62 (0.52) 1.15 (0.17) 4.07 (0.62)
p * 0.41 0.51 0.47 0.32
Weight change, kg
Unknown 8 2.31 (1.73) 4.19 (1.22) 1.10 (0.35) 3.84 (0.45)
<4.1 265 2.09 (1.31) 4.53 (0.56) 1.17 (0.16) 3.94 (0.62)
≥4.1 277 2.17 (1.70) 4.74 (0.56) 1.13 (0.15) 4.25 (0.64)
p * 0.57 <0.01 0.01 <0.01
Diabetes
Unknown 6 1.73 (1.10) 4.0 (1.38) 1.09 (0.41) 3.74 (0.46)
No 388 2.15 (1.63) 4.61 (0.57) 1.14 (0.15) 4.09 (0.60)
Type 1 14 2.69 (1.44) 4.55 (0.48) 1.04 (0.09) 4.37 (0.43)
Type 2 142 2.04 (1.19) 4.72 (0.58) 1.18 (0.18) 4.09 (0.76)
p * 0.29 0.13 <0.01 0.28
Post-menopausal
Unknown 6 1.73 (1.10) 4.0 (1.38) 1.09 (0.41) 3.74 (0.46)
No 463 2.14 (1.55) 4.63 (0.56) 1.14 (0.15) 4.11 (0.65)
Yes 81 2.13 (1.36) 4.70 (0.59) 1.18 (0.19) 4.05 (0.62)
p * 0.99 0.29 0.05 0.43
Data are presented as the mean (standard deviation; SD) of each thyroid biomarker (i.e., TSH, fT3, fT4, fT3:fT4),
according to categories of participant characteristics (i.e., age, weight change, diabetes status, menopause status).
* Bolded p-values represent significant global differences in the levels of each thyroid biomarker across non-missing
categories of participant characteristics.
Table A2. Associations between lactation duration and fT3 and the fT3:fT4 ratio by menopausal status
among women with a history of gestational diabetes, Diabetes & Women’s Health Study.
Thyroid
Biomarker
Pre-Menopausal Women
(n = 463)
p-Trend *
Post-Menopausal Women
(n = 81)
p-Trend *
n Adjusted
1 β
Estimate (95% CI)
n Adjusted
1 β
Estimate (95% CI)
fT3 (pmol/L) 0.29 0.22
≥12 months 190 0.10 (−0.08, 0.28) 20 0.47 (0.04, 0.90)
6 to <12 months 137 0.12 (−0.07, 0.03) 33 0.10 (−0.30, 0.50)
<6 months 87 0.02 (−0.17, 0.22) 17 0.46 (0.03, 0.90)
None 49 Reference 11 Reference
fT3:fT4 ratio 0.43 0.33
≥12 months 190 0.00 (−0.20, 0.21) 20 0.38 (−0.06, 0.82)
6 to <12 months 137 0.05 (−0.17, 0.27) 33 −0.12 (−0.53, 0.29)
<6 months 87 −0.11 (−0.34, 0.12) 17 0.14 (−0.30, 0.59)
None 49 Reference 11 Reference
1 Model was adjusted for the following covariates, measured at the index pregnancy: age, pre-pregnancy
body mass index (unknown, <25, 25–29.9, ≥30.0 kg/m2), occupation (unknown, professional, skilled worker,
unskilled/unemployed/student), nulliparity (unknown, yes, no), smoking during pregnancy (unknown, any, none),
and alcohol during pregnancy (unknown, any, none). * p-trend values represent linear trends in thyroid biomarker
levels with increasing lactation duration. We assessed p-trends by using the median for each category of lactation
duration as a continuous exposure.
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